Clinical Trial Update: Aranesp® Monthly Preference Study - 2 [Phase 4]

View source ↗

Summary

Phase 4 Aranesp monthly preference study in kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Kidney Disease | Phase 4 | Status: COMPLETED